A series of platforms have been launched for CTC detection in clinical and research settings: CellSearch, the first and the only Food and Drug Administration (FDA) approved CTC test, detect CTCs in patients with breast, colorectal, and prostate cancer (EpCAM+, cytokeratin 8+, 18+ and/or 19+ and CD45−); Epic Sciences capture CTCs and classify them based on molecular markers (EpCAM, cytokeratins, HER2, androgen receptors, etc.)and morphological features including size and shape. Here, EPCAM is linked to Familial prostate cancer.